PSY30 Cost Utility Analysis of the Profilaxis Versus On-Demand Treatment With Recombinant Factor IX for the Treatment of Hemophilia B in Mexico  by Muciño-Ortega, E. et al.
utilization, lower QoL and greater work impairment. Additional research is war-
ranted to further characterize the impact of cost and reimbursement on patient
outcomes.
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OBJECTIVES: Limited data exist on the economic impact of SLE flares. This study
estimatedHRUand costs of SLE flares in aU.S.Medicaid population.METHODS: SLE
Patients 18 years old were extracted from a large Medicaid database 2002-2009.
Index date was the date of the first SLE diagnosis. All patients were continuously
enrolled for6months before and12months after index date and followed until
the earliest of inpatient death, end of enrollment, or end of study. Mild, moderate,
and severe flareswere identified in the follow-up period. Costs attributable to flares
weremeasured during 30 days following a flare. If a flare of higher severity occurred
within 30 days, the length was limited to the period up to the start of the new flare.
RESULTS: 14,262 patients met the study criteria and 97% experienced at least one
flare during an average follow-up of 39 months (3,540 had severe, 9,597 had mod-
erate, and 669 hadmild flares as theirmost severe flares). Mean costs per flarewere
$11,716, $562 and $129 for severe, moderate, and mild flares, respectively. Patients
with 1 severe flares during follow-up had 1.7 inpatient (IP) admissions, 3.5 emer-
gency room (ER) visits, and 16.0 outpatient (OP) visits with a total medical cost of
$49,754per year. Patients with 1 moderate flares but no severe flares had 0.9 IP
admissions, 2.4 ER visits, and 12.8 OP visitswith a cost of $21,941. Patientswith only
mild flares had the least HRU of 1.0 IP admission, 1.5 ER visits, and 7.5 OP visits with
a cost of $17,574. Patients with severe andmoderate but nomild flares and patients
with severe flares only incurred the highest annual cost ($66,412 and $74,491,
respectively). CONCLUSIONS: Flares occurred in almost all SLE patients and were
associated with a significant economic burden.
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OBJECTIVES: Immune tolerance induction (ITI) is generally accepted as first choice
treatment to eradicate inhibitors in hemophilia A patients. Little is known about
the outcomes and cost consequences of this treatment option. METHODS: The
Immune Tolerance and Economics Retrospective (ITER) study is an observational,
retrospective, multicentre, multinational study aiming to estimate cost of treat-
ment in hemophilia A patients, undergoing ITI. Data on hemostatic treatment
given in the following time periods were collected: up to 12 months before the
diagnosis of Inhibitors, between Inhibitors diagnosis and ITI start, during ITI, and
12 months after the end of ITI. Costs of treatment were calculated in the perspec-
tive of the third party payer and expressed as mean €/patient-month. RESULTS:
Seventy-one valid patients, with median age at ITI start3.8 (0.4-41) years, were
enrolled. Before ITI the median Inhibitors peak titre was 18.5 (0.80-704) BU. ITI was
applied for a mean of 1.85 (0.1-14.0) years and was successful in 84.5% pts. Before
Inhibitors diagnosis, patients cost was 670.2 €/patient-month. Cost was 3,188€/
patient-month between the Inhibitors diagnosis and ITI start (92.1% for bypassing
agents), and 60,078€ during ITI (76.8% for ITI, 19.4% for extra FVIII treatment, 3.8%
for extra treatment with bypassing agents). The mean cost after ITI was
13,211€/patient-month. CONCLUSIONS: ITI applied on patients with the character-
istics of those involved in the ITER study is successful in 84% of themat amean cost
of 60,000€/patient-month during ITI, plus 13,000€/patient-month through 1 year
later. Further research is encouraged to value long term benefits and costs attrib-
utable to ITI versus other treatment options, in order to identify the most efficient
treatment for the patients and for the health care system.
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OBJECTIVES: Limited information is available on the cost effectiveness of newer
biologic agents for treatment of psoriasis. The objective of this study is, from a
United States societal perspective, to compare the cost-effectiveness of etanercept
and ustekinumab therapy in patients with moderate-to-severe psoriasis based on
head-to-head clinical trial information. METHODS: A Markov model was con-
structed to simulate the incremental cost per quality-adjusted life year gained.
Costs were estimated from the societal perspective in the United States over a time
horizon of five years. All cost and effectiveness estimates were obtained from the
relevant literature. An annual discount rate of 3%was applied to costs and quality-
adjusted life years. All costs were adjusted to 2011 US dollars. One-way and thresh-
old sensitivity analyses assessed the robustness of model results. RESULTS: In the
base case, over a 5-year time horizon, ustekinumab 45 mg was dominant versus
etanercept 50 mg. The base case incremental cost-effectiveness ratio (ICER) com-
paring ustekinumab 90 mg with etanercept 50 mg averaged $267,761 per QALY
gained. The ICER comparing ustekinumab 90mgwith ustekinumab 45mgaveraged
$915,179 per QALY gained. ICERs were quite sensitive to unit prices for usteki-
numab and etanercept. CONCLUSIONS: Given the limitations of the available data,
ustekinumab 45 mg was dominant over etanercept 50 mg for a five-year time
horizon, whereas ustekinumab 90 mg was more costly and marginally more effec-
tive than etanercerpt 50 mg. Ustekinumab 90 mg would not be considered cost
effective using a US willingness-to-pay threshold of $120,000-150,000 per QALY.
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OBJECTIVES: Patients with chronic pain due to osteoarthritis (OA) or rheumatoid
arthritis (RA) do not often obtain adequate relief or experience unacceptable side
effects due their pain-control treatments. The objective of this study was to per-
form a cost-effectiveness analysis comparing celecoxib, etoricoxib and lumira-
coxib in the treatment of chronic pain in patients with OA and RA, from the Mex-
ican Social Security Institute (IMSS) perspective.METHODS: A decision-tree model
(12-weeks time horizon) was used to compare pain reduction and direct medical
costs associated to competing alternatives. A systematic literature reviewwas per-
formed to identify the pain reduction (reported through visual analogue scales) and
adverse events (AE) incidence rate associated. Comparatorswere: celecoxib 200mg/
day, etoricoxib 90mg/day and lumiracoxib 100mg/day for patients with OA and RA.
A meta-analysis with selected publications (n10) was performed. Resource utili-
zationwas extracted from clinical practice guidelines and unit costswere retrieved
from IMSS official sources. Probabilistic sensitivity analysis was performed. Ac-
ceptability curves were developed. RESULTS: Pain reductions vs. placebo were:
celecoxib 14.18% (CI95% 10.48-17.87, p0.00001); etoricoxib 12.70% (7.67-17.73,
p0.00001) and lumiracoxib 9.47% (7.17-11.77, p0.00001). Differences between
celecoxib and lumiracoxib was meaningful (p0.05). The odds ratios of AE inci-
dence vs. placebo were: 1.06 (0.77-1.46, p0.37); 1.09 (0.87-1.36, p0.73) and 1.44
(0.88-2.34, p0.14), respectively. The expected medical costs (2011 US$) were:
$197.93 ($9.52); $221.54 ($7.06) and $306.65 ($12.86), respectively. The cost of
management of AE contributed with $101.28, $95.00 and $146.17 of the overall
expected costs, respectively. In regards to etoricoxib (basecase), celecoxib showed
to be a cost-saving strategy with a cost-effective proportion of 76.7% (74.1%-79.3%);
while lumiracoxib was the less effective and more costly strategy. CONCLUSIONS:
At IMSS, celecoxib patients who suffer OA or RA would reach a higher incremental
reduction in pain intensity at 12 weeks reducing overall costs in comparison to
etoricoxib.
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OBJECTIVES: In the French setting, uncontrolled bleeding episodes in hemophilia
patients with inhibitors require emergency/inpatient care. The impact of on-de-
mand (OD) treatment of bleeding episodes remain rarely quantified in France.
METHODS:Wemodeled the lifetime number of bleeding episodes and hospitaliza-
tions associated with recombinant activated Factor VIIa (rFVIIa) and plasma-de-
rived activated prothrombin complex concentrate (pd-aPCC) to investigate the im-
pact of faster bleeding resolution of a new bypassing agent (BA) by applying
hypothetical adjustments to the performance of rFVIIa. The exploratory semi-
Markov model assumed a French payer perspective and simulated treatment of
2-year oldmale hemophilia patientswith high-responding inhibitors.Model inputs
were obtained from published international studies and French government
sources. Comparisons of the current BAs pertaining to dosing and base-case effi-
cacy rates were obtained from a Bayesian meta-analysis pooling available esti-
mates. Model outcomes included the rate of hospitalization due to uncontrolled
bleeds and number of minor/major bleed over lifetime. Sensitivity analyses were
performed to test robustness of the model. RESULTS: rFVIIa required 4% fewer
hospitalizations for bleed treatment than pd-aPCC, as well as a reduction in life-
time bleeds. rFVIIa resulted in 667 minor bleeds over the patient’s lifetime com-
pared with 673 in patients treated with pd-aPCC. When adopting potential im-
provements for a hypothetical new BA, faster bleed resolution that results in fewer
rebleeds reduces hospitalizations by 13% in the rFVIIa arm compared to base case.
CONCLUSIONS: Additional research is needed to understand how increased bleed
control and faster resolution of bleeds in French inhibitor patients translate into a
reduction in other health resources utilization such as emergency visits to hemo-
philia treatment centers and indirect costs including missed school/productivity
loss which can improve the quality of life of patients and caregivers.
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OBJECTIVES: Hemophilia B is a rare and expensive to treat disease. The aim of this
studywas to develop an economic evaluation of prophylactic vs on-demand supply
of recombinant factor IX (rFIX) in the treatment of patients with severe hemophilia
B, from the Social Security Mexican Institute (IMSS) perspective. METHODS: A
three-state Markovmodel (two-week cycles) followingmale patients from birth up
to 75 years was developed to estimate the cost and outcomes of prophylactic (30
IU/kg body weight/week) and on-demand (40 IU/kg body weight/joint bleed) ap-
proaches to manage haemophilia B. On-demand was considered the usual prac-
tice. Effectiveness measure was the QALY. A literature review was performed to
extract Mexican demographic and general epidemiologic data needed to populate
the model. Treatment cost data (inpatient, outpatient, emergency services, medi-
cines, laboratory and image studies) were extracted fromMexican published data-
bases (the acquisition cost of rFIX was provided by the manufacturer). Health and
economic consequences were assessed in different age groups. Both costs and
outcomes were discounted at 5% annual rate Probabilistic sensitivity analyses and
acceptability curves were constructed. RESULTS: Cost of rFIX in prophylaxis rep-
resented 60.3% and 90.4% of the total annual cost in the 4 years and 19 years
groups, respectively. In on-demand approach, the cost of the therapy represented
45.3% and 83.9% in the4 years and19 years group, respectively. The incremen-
tal effectiveness for rFIX is close to one QALY in all age groups. The ICER of pro-
phylaxis in patients 4, 5-9, 10-14, 15-19, 19 years old was US$5,281.33,
US$14,586, US$15,172, US$20,398 and US$40,291/QALY gained, respectively. Ac-
ceptability curves showed an inverse relationship between age and cost-effective
proportion.CONCLUSIONS:At IMSS setting, the prophylaxiswith rFIX for theman-
agement of patients suffering severe hemophilia B appears to be a highly cost-
effective and a cost-effective intervention in children and teenagers, respectively.
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OBJECTIVES: Migraine is a common central nervous system disorder. The burden
of migraine is substantial due to its high prevalence and prominent temporary
disability. This study investigates the application of cost-effectiveness analysis,
from the Korean health care system perspective, for the comparison of eletriptan
40mg and sumatriptan 50mg in the acute treatment ofmigraine attack.METHODS:
A decision tree model was developed to estimate migraine treatment cost and
efficacy. Clinical data was derived from a clinical trial comparing oral eletriptan to
oral sumatriptan (G. Sandrini, 2002). Efficacy measures consisted of “pain-free at 2
hours (PF2)” and “sustained pain free for 2-24 hours (SPF)”. Drug costs for initial
dosing, second dosing for relapse, physician visit cost, and emergency visit cost
were taken into account. Citing 2008 HIRA report, physician visit cost and emer-
gency visit cost were calculated. All costs converted into 2011 Korean Won (KRW).
The time horizonwas a singlemigraine attack. RESULTS: In the base-case analysis,
assuming the eletriptan 40mg drug cost (4,775 KRW) is 20% higher than su-
matriptan 50mg drug cost (3,979 KRW), the average cost-effectiveness ratio (ACER)
were 23,702 KRW and 36,239 KRW (per attack at which PF2 is achieved) for
eletriptan 40mg and sumatriptan 50mg, respectively. Also, ACER for SPF per attack
is achieved was 26,054 KRW and 40,837 KRW for eletriptan 40mg and sumatriptan
50mg, respectively. CONCLUSIONS: Although eletriptan 40mg is more costly than
sumatriptan 50mg, because of eletriptan 40mg’s superior efficacy, the ACER of
eletriptan 40mg was lower than sumatriptan 50mg in the treatment of migraine
attack, with respect to PF2 and SPF aspects. Eletriptan 40mg has a potentially im-
portant role to play in the cost-effective management of migraine.
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OBJECTIVES: Pain management is an important dimension of postsurgical care.
The aim of this study was to determine the cost-effectiveness of parecoxib, mor-
phine, buprenorphine and ketorolac in themanagement of postsurgical pain, from
the perspective of the Mexican Social Security Institute (IMSS).METHODS: A deci-
sion-tree model was used to assess the outcomes of parecoxib 40mg; buprenor-
phine 0.12, 0.18 and 0.36mg;morphine 4, 6 and 12mg and ketorolac 30mg inwomen
who received them in the morning after their gynecologic surgery. In case of fail-
ure, rescue therapy with morphine 4mg was allowed. The time horizon is 12 hours
after the medication was received. Only the acquisition cost was considered (2011
US$). The effectiveness outcome was the proportion of respondents who experi-
enced onset of analgesia and rated their medication as “good” or “excellent”
(through patient=s global evaluation of the study medication questionnaire). Liter-
ature reviewwas performed to extract the clinical outcomes of competing alterna-
tives (the doses of morphine 4mg, buprenorphine 0.12mg and so on, were consid-
ered equianalgesic). Acquisition costs were extracted from official institutional
sources. The results of the analysis are expressed through the ICER (ketorolac as
basecase). Univariate sensitivity analysis was performed. RESULTS: The propor-
tion of respondents treated withmorphine 4mg-buprenorphine 0.12mg, morphine
6mg-buprenorphine 0.18mg, morphine 12mg-buprenorphine 0.36mg, ketorolac
and parecoxib was 44.21%; 44.21%; 46.42%; 63.64% and 71.76%, respectively. The
expected cost per patient ofmorphine 4mg, buprenorphine 0.12mg,morphine 6mg,
buprenorphine 0.18mg, morphine 12mg, buprenorphine 0.36mg, ketorolac and
parecoxib was $4.53; $1.45; $6.32; $1.71; $11.69; $2.48; $0.84 and $7.12, respectively.
All the alternatives (except parecoxib, ICER: $77.30) are dominated by ketorolac.
Furthermore, parecoxib ismore effective than competing alternatives but only less
expensive than morphine 12mg. CONCLUSIONS: At IMSS setting, parecoxib ap-
pears to be cost-saving regarding morphine 12mg and cost-effective regarding ke-
torolac, buprenorphine and morphine 4 and 6mg.
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OBJECTIVES: Based on an economic evaluation of cost-effectiveness of frontline
dasatinib treatment for chronic myeloid leukemia by the York Consortium and
after transferability analysis of data, we performed an adaptation of this model in
Colombia and Venezuela. We compared the costs and cost-effectiveness ratio of
dasatinib 100 mg/day versus imatinib 400 mg/day and nilotinib 600 mg/day as
frontline treatment for CML in its three phases. with increases to 140 mg/day of
dasatinib, 800 mg/day of imatinib and 800 mg/day nilotinib in a second-line
therapy. METHODS: The original model considered those patients with CML who
had not received previous treatment and a Markov=s model with probabilities of
change for the chronic, accelerated and death phases, over the lifetime and with a
costs and benefits discount rates of 3.5%. Direct medical and treatment cost and
mortality rates were taken from the local jurisdiction and WHO life tables. The
results of the model included the costs of each alternative treatment with dasat-
inib, nilotinib or imatinib and the QALYs (Quality Adjusted Life Years). Costs are
expressed in 2011 Colombian pesos and Venezuelan strong bolivars. RESULTS:
Dasatinib 100 mg/day as frontline treatment for CML produced the greatest num-
ber of QALYs, both in Colombia and Venezuela with 10.67 and 10.53 QALYs respec-
tively, comparedwith imatinib; 10.10 and 9.97 QALYs and nilotinib; 10.50 and 10.36
QALYs Dasatinib 100 mg/day was also more cost-effective than nilotinib as front-
line treatment for CML, being dominant in both these countries. CONCLUSIONS: In
the frontline treatment for CML in Colombia and Venezuela, Dasatinib was more
effective than imatinib and nilotinb and showed better rates of cost-effective than
nilotinib been dominant in both countries. Although there was an increase in over-
all costs, this is due to the increase in life years gained and thus in greater use of
medical resources and medications.
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OBJECTIVES: Metabolic Syndrome (MetS) is defined as a clustering of risk factors
for diabetes mellitus (T2DM) and cardiovascular disease (CVD) which puts individ-
uals at increased risk of developing these conditions and consequently leads to a
reduction in life expectancy and increased morbidity. METHODS: A systematic
review and network meta-analysis was undertaken to assess the relative clinical
effectiveness of a number of lifestyle and pharmacological interventions, both
independently and in combination. A second systematic review, and series of
meta-analyses, was also undertaken to estimate the increased burden that a MetS
diagnosis has on the subsequent risk of T2DM, CVD and all-causemortality. A fully
probabilistic economic Markov decision model was developed in WinBUGS, and
which directly included the series of meta-analyses above, in order to assess the
cost-effectiveness of the various interventions. RESULTS: The use of both lifestyle
and pharmacological interventions in combination was dominated in the incre-
mental cost-effectiveness analysis, with the use of both of them independently
producing greater health gain at lower cost. Pharmacological intervention was
cost-effective compared to standard care (ICER £3050 with a probability of 0.53 at a
threshold value of £20K/QALY), and lifestyle intervention was cost-effective com-
pared to pharmacological (ICER £6933with a probability of 0.52 at a threshold value
of £20K/QALY). A series of sensitivity analyses were also undertaken both with
regards to the model inputs/distributions and a number of methodological as-
sumptions, but the results remained largely insensitive to these changes.
CONCLUSIONS: The use of a lifestyle intervention would appear to be a potentially
cost-effective treatment strategy for adults with MetS, however considerable un-
certainty surrounds this decision. The use of a comprehensive approach to eco-
nomic modelling within a WinBUGS framework allowed distributional assump-
tions to be relaxed, sources of correlation to be appropriately accounted for, and
more complex sensitivity analyses to be easily undertaken.
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ECONOMIC EVALUATION OF LENALIDOMIDE IN THE MANAGEMENT OF
PREVIOUSLY TREATED MULTIPLE MYELOMA (PTMM) PATIENTS IN GREECE
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OBJECTIVES: To assess the cost-effectiveness of lenalidomide with dexametha-
sone (Len/Dex) combination relative to bortezomib alone, in previously treated
multiple myeloma patients in Greece. METHODS: A discrete event simulation
model was locally adapted, to estimate the differences in the overall survival and
treatment cost for the two alternative options. Efficacy data utilized came from the
two large,multicenter, controlled, randomized clinical trials for the first option and
an open label study for the second. Quality of life data were extracted from inter-
national sources. Data on resource use and prices were collected from the elec-
tronic databases of local hospitals and other relevant sources. The perspective of
the analysis was that of payers. Total cost accounts for themonitoring and admin-
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